$468 $279 for your first year. Make up your own mind. Build robust opinions with the FT’s trusted journalism. Offer available here until 24th October.

With early phase 1 data now out in the wild, metabolic disease outfit Metsera is wasting no time locking down supplies of its ...

In this article, we will discuss: 12 Best Growth Stocks To Buy According To Hedge Funds.

Demand forweight-loss drugs has grown at an astonishing rate in recent years, driving share prices of healthcare giants such ...

Roche told investors on Monday that it plans to make significant cuts to both the cost and time it takes for it to develop ...

With the third quarter of 2024 ending, the discourse on the stock market for global equities has shifted back to interest ...

Roche said on Monday that three early-stage obesity and diabetes drug candidates from its acquisition of Carmot Therapeutics ...

People who take Novo Nordisk's semaglutide-based injectables Ozempic and Wegovy seem to be way less likely to die from ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

Sen. Bernie Sanders’ aggressive targeting of Danish drugmaker Novo Nordisk’s Ozempic and Wegovy pricing, and not Eli Lilly’s ...

Sima Sistani, CEO of WeightWatchers, announced her departure from the weight-loss company, which has struggled to adapt in ...

Thousands of plaintiffs have sued Ozempic manufacturers for failing to warn them about the risk of stomach paralysis.